Durvalumab Shows Few High-Grade AEs in Cutaneous T-Cell Lymphoma
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Related Articles
Epcoritamab Monotherapy Induces Complete Responses in R/R CLL
Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.
Olverembatinib May Be Effective in Second Line for CP-CML
Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.
Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma
Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.
FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC
The FDA granted breakthrough therapy designation to Dato-DXd for previously treated EGFR-mutated advanced non–small cell lung cancer.
NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET
NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.
State Cancer Profiles
State Cancer Profiles is an interactive map engine produced in collaboration between the National Cancer Institute and Centers for Disease Control and Prevention. It was…
China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC
Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.
ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancer
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in…
Focus | Innovative Cancer Care | Elekta
Explore cutting-edge cancer treatment and healthcare innovations in Focus, Elekta’s Online Magazine. Stay informed with the latest articles. Discover more.
Here’s why more Ohioans should be screened for lung cancer
Early diagnoses can significantly improve lung cancer patients’ survival chances, and new screening technologies can help doctors catch cases at more treatable stages.
